Publication:
Correction to: Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study (Clinical Drug Investigation, (2018), 38, 9, (853-865), 10.1007/s40261-018-0678-5)

dc.contributor.authorSermsiri Sangroongruangsrien_US
dc.contributor.authorUsa Chaikledkaewen_US
dc.contributor.authorSuthasinee Kumluangen_US
dc.contributor.authorOlivia Wuen_US
dc.contributor.authorClaudia Geueen_US
dc.contributor.authorTanapat Ratanapakornen_US
dc.contributor.authorPattara Leelahavarongen_US
dc.contributor.authorLily Ingsrisawangen_US
dc.contributor.authorPaisan Ruamviboonsuken_US
dc.contributor.authorWongsiri Taweebanjongsinen_US
dc.contributor.authorJanejit Choovuthayakornen_US
dc.contributor.authorApichart Singalavanijaen_US
dc.contributor.authorPrut Hanutsahaen_US
dc.contributor.authorKittisak Kulvichiten_US
dc.contributor.authorThitiporn Ratanapojnarden_US
dc.contributor.authorWarapat Wongsawaden_US
dc.contributor.authorYot Teerawattananonen_US
dc.contributor.otherChulalongkorn Universityen_US
dc.contributor.otherRangsit Universityen_US
dc.contributor.otherKasetsart Universityen_US
dc.contributor.otherKhon Kaen Universityen_US
dc.contributor.otherFaculty of Medicine, Ramathibodi Hospital, Mahidol Universityen_US
dc.contributor.otherThailand Ministry of Public Healthen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherFaculty of Medicine, Siriraj Hospital, Mahidol Universityen_US
dc.contributor.otherPhramongkutklao College of Medicineen_US
dc.contributor.otherUniversity of Glasgowen_US
dc.contributor.otherChiang Mai Universityen_US
dc.contributor.otherMettapracharak (Wat Rai Khing) Hospitalen_US
dc.date.accessioned2020-01-27T10:11:53Z
dc.date.available2020-01-27T10:11:53Z
dc.date.issued2019-01-31en_US
dc.description.abstract© 2019, The Author(s). The Open Access license, which previously read: Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creat iveco mmons .org/licen ses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. Should read: Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http:// creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The original article has been corrected.en_US
dc.identifier.citationClinical Drug Investigation. Vol.39, No.1 (2019), 115en_US
dc.identifier.doi10.1007/s40261-019-00747-yen_US
dc.identifier.issn11791918en_US
dc.identifier.issn11732563en_US
dc.identifier.other2-s2.0-85060336580en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/51947
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85060336580&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleCorrection to: Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study (Clinical Drug Investigation, (2018), 38, 9, (853-865), 10.1007/s40261-018-0678-5)en_US
dc.typeErratumen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85060336580&origin=inwarden_US

Files

Collections